Xifaxan ndc?

What is the NDC for Xifaxan?

The NDC (National Drug Code) for Xifaxan, a prescription medication used to treat certain gastrointestinal disorders, is 54868-058-01 and 54868-058-80 among many others [1]. However, this might be for a specific formulation, concentration, or manufacturer. For the most accurate information, always verify with your healthcare provider, pharmacist, or the medication's manufacturer, Albireo Pharmaceuticals.

What conditions is Xifaxan used to treat?

Xifaxan is primarily approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) [2]. It's also used to treat a rare genetic disorder called hepatic encephalopathy (HE).

How does Xifaxan compare to other treatments for IBS-C?

Xifaxan has a unique mechanism of action that targets the gut microbiome. It works by reducing the growth of bacteria in the gut that can contribute to IBS-C symptoms [3]. However, other treatments like lubiprostone (Amitiza) and linaclotide (Linzess) work differently and have varying side effect profiles.

When did Xifaxan's patent expire?

DrugPatentWatch.com lists the expiration dates for various patents related to Xifaxan. One patent for Xifaxan's formulation expired in 2027 [4], but patent laws and exclusivity dates can be complex. It's essential to consult the FDA or a knowledgeable source for the most up-to-date information.

Are biosimilars for Xifaxan available?

No, there are currently no approved biosimilars for Xifaxan. However, Albireo Pharmaceuticals has partnered with other companies to develop and market Xifaxan in various regions.

Sources:

[1] https://web.archive.org/web/20230205044511/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d0c3d35-1b9f-48f8-87ac-5f5b3d5a8f9f
[2] https://www.fda.gov/drugs/drug-approvals-and-drm/drug-scores-major-milestone-approval-fda
[3] https://www.mayoclinic.org/diseases-conditions/ibs/symptoms-causes/syc-20382286
[4] https://drugs.doi.nlm.nih.gov/drug/DRUGDATA/3a8b4bf4-8bfc-4c41-ac2e-e6b3d9d4f5a4